Evidence map›Paper›PMID 27604320›Full record

ArticleScientific reports2016

Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.

Shunpei Satoh, Atsushi Takatori, Atsushi Ogura, Kenichi Kohashi, Ryota Souzaki, Yoshiaki Kinoshita, Tomoaki Taguchi, Md Shamim Hossain, Miki Ohira, Yohko Nakamura and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Shunpei SatohChildren's Cancer Research Center, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Atsushi TakatoriChildren's Cancer Research Center, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Atsushi OguraChildren's Cancer Research Center, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Kenichi KohashiDepartment of Anatomic Pathology, Graduate School Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan, Chiba 260-8670, Japan.
Ryota SouzakiDepartment of Pediatric Surgery, Graduate School Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Yoshiaki KinoshitaDepartment of Pediatric Surgery, Graduate School Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Tomoaki TaguchiDepartment of Pediatric Surgery, Graduate School Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Md Shamim HossainChildren's Cancer Research Center, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Miki OhiraDivision of Cancer Genomics, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Yohko NakamuraDivision of Biochemistry &Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Akira NakagawaraChildren's Cancer Research Center, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Chiba Cancer Center · JPKyushu University · JPChiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In neuroblastoma (NB), one of the most common paediatric solid tumours, activation of anaplastic lymphoma kinase (ALK) is often associated with poor outcomes. Although genetic studies have identified copy number alteration and nonsynonymous mutations of ALK, the regulatory mechanism of ALK signalling at protein levels is largely elusive. Neuronal leucine-rich repeat 1 (NLRR1) is a type 1 transmembrane protein that is highly expressed in unfavourable NB and potentially influences receptor tyrosine kinase signalling. Here, we showed that NLRR1 and ALK exhibited a mutually exclusive expression pattern in primary NB tissues by immunohistochemistry. Moreover, dorsal root ganglia of Nlrr1+/+ and Nlrr1-/- mice displayed the opposite expression patterns of Nlrr1 and Alk. Of interest, NLRR1 physically interacted with ALK in vitro through its extracellular region. Notably, the NLRR1 ectodomain impaired ALK phosphorylation and proliferation of ALK-mutated NB cells. A newly identified cleavage of the NLRR1 ectodomain also supported NLRR1-mediated ALK signal regulation in trans. Thus, we conclude that NLRR1 appears to be an extracellular negative regulator of ALK signalling in NB and neuronal development. Our findings may be beneficial to comprehend NB heterogeneity and to develop a novel therapy against unfavourable NB.

Indexed as

Anaplastic Lymphoma KinaseAnimalsBrain NeoplasmsCell Line, TumorCell ProliferationExtracellular SpaceGanglia, SpinalHEK293 CellsHumansMembrane ProteinsMiceNeoplasm ProteinsNerve Tissue ProteinsNeuroblastomaPhosphorylationProtein BindingALK protein, humanAlk protein, mouseAnaplastic Lymphoma KinaseLRRN1 protein, humanLrrn1 protein, mouseMembrane ProteinsNeoplasm ProteinsNerve Tissue ProteinsReceptor Protein-Tyrosine Kinases

Identifiers

PMID27604320
PMCPMC5015029
OpenAlexW2514914753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.